Rubina Begum

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

R.D. James, Rob Glynne‐Jones, Helen Meadows et al. · The Lancet Oncology · 2013 · 733 citations · Full text

Medicine, Oncology, Radiation Oncology +12

Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial

Rob Glynne‐Jones, David Sebag‐Montefiore, Helen Meadows et al. · The Lancet Oncology · 2017 · 183 citations · Full text

Medicine, Radiation Oncology, Clinical Radiation Oncology +1

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial

Rob Glynne‐Jones, Latha Kadalayil, Helen Meadows et al. · Annals of Oncology · 2014 · 53 citations · Full text

Medicine, Oncology, Surgery +13

Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II.

Rob Glynne‐Jones, R.D. James, Helen Meadows et al. · Journal of Clinical Oncology · 2012 · 43 citations

Medicine, Oncology, Radiation Oncology +16

NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

Kai‐Keen Shiu, Yanrong Jiang, Mark Saunders et al. · Journal of Clinical Oncology · 2024 · 33 citations

Pharmacy, Oncology, Pharmacotherapy +17